Navigation Links
AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
Date:3/6/2009

SAN DIEGO, March 6 /PRNewswire/ -- AndroScience Corporation (ASC(TM)), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9(TM) cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.

ASC-J9(TM) demonstrated a clinical benefit in reducing inflammatory lesions compared to placebo at certain dosages and at multiple time points during the study, though the study was not powered for statistical significance. ASC will now focus on bolstering efficacy through a new formulation and intends on forming a co-development or licensing partnership for future clinical development and commercialization. Through enhancing androgen receptor protein degradation, ASC-J9(TM) represents the first topical agent directed at modulating the effect of androgens (male hormones), through the androgen receptor, a key causative factor in the pathogenesis of acne.

Charles Shih, Ph.D., Chief Executive Officer of AndroScience Corporation, said, "We are extremely enthusiastic about the therapeutic potential of ASC-J9(TM) and the remarkable safety profile exhibited by the drug. The 0.025% cream formulation dose of ASC-J9(TM) delivered a therapeutic benefit comparable to levels seen with marketed acne drugs on inflammatory lesions, with no side effects, and we believe a higher dosage or improved formulation will translate to even greater efficacy in the treatment of acne."

ASC-J9(TM) is a small molecule with a novel mechanism of action, which selectively enhances androgen receptor degradation (ARD) to reduce androgen activity. ARD enhancers act on a key cause of acne, the androgen activation system, through reducing high levels of androgen receptor present in the sebaceous gland to lower sebum secretion, a fundamentally different approach from all other current acne treatments. ASC-J9(TM) cream is topically administered and exhibits low systemic absorption, limiting systemic side effect risks and allowing for the treatment of both males and females.

In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based approaches.

AndroScience Corporation

www.androscience.com


'/>"/>
SOURCE AndroScience Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets
4. Christie Cookie Recalls Certain Lots of Peanut Butter Cookie Dough Due to Expanded Recall by Peanut Corporation of America
5. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
6. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
7. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
10. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
11. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
(Date:7/10/2017)... , July 10, 2017  BDI Group subsidiary ... patient support services organization serving specialty pharmacies, home ... launch of four significant, value-added member programs designed ... better manage reimbursement and improve access and affordability ... therapies. ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, ... awareness for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... of long term skin conditions, including cancer. In the short term, overexposure ...
(Date:7/24/2017)... ... 24, 2017 , ... A CDC study shows that, although people are taking more steps to ... 29), had at least one case of sunburn within the past year. It’s common and ... ignore the issue. However, only recently have people become conscientious of the risks that accompany ...
(Date:7/24/2017)... ... 2017 , ... Anyone who uses scales know they have limits; a small ... that same scale to dispense medication. The first example is an issue of capacity, ... it is important to have the right balance for the process. METTLER TOLEDO’s new ...
(Date:7/24/2017)... OR (PRWEB) , ... July 24, 2017 , ... Sharon ... Climate Change and Your Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked ... the rise of myopia in China. , The article by Zidor Aldama described the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report ... invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of ... Allergan is bringing a newly defined structure to the aesthetics market. Dr. Vitenas ...
Breaking Medicine News(10 mins):